It is well-settled that fraud-based claims asserted in federal court need to satisfy not only Federal Rule of Civil Procedure 12(b)(6)’s plausibility pleading standard but also the heightened pleading ...
When the Federal Circuit resurrected Amarin’s “skinny label” infringement claims against Hikma last month, it offered some important lessons for drug developers. The precedential decision helps ...
The company was accused of misleading California consumers with health and nutrition claims on the labels for PediaSure—a nutritional supplement for children—because of the amount of added sugar in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results